Company Profile
Intensity Therapeutics Stock Price, News & Analysis
- Ticker:
- INTS
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
4.25 USD (+1.19%)
Close
Last updated: August 6, 2026
11.6M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, INTS closed up 1.19% at $4.25. No new same-company headline was identified in the current news window.
Company overview
Intratumoral Cancer Therapy
Intensity Therapeutics develops medicines administered directly into tumors. Its approach is designed to kill injected tumor cells, expose tumor antigens and stimulate a broader immune response.
INT230-6
INT230-6 combines cytotoxic agents with a proprietary dispersion molecule intended to improve penetration throughout solid tumors. The candidate is being studied both before surgery and in advanced disease.
Breast-Cancer Programs
The INVINCIBLE-4 study evaluates presurgical INT230-6 in triple-negative breast cancer, while INVINCIBLE-3 studies the candidate in a broader breast-cancer setting.
Future catalysts
Resumption of enrollment in INVINCIBLE-4 in the second quarter of 2026.
Resumption of enrollment at selected U.S. INVINCIBLE-3 sites by the third quarter of 2026.
Recent news
- 01
Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026
Source: Intensity Therapeutics
- 02
- 03
- 04
Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award
Source: Intensity Therapeutics
- 05
Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Source: Intensity Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Intensity Therapeutics (INTS)?
Intensity Therapeutics (INTS) most recently closed at 4.25 USD, a +1.19% move versus the previous session.
What is the market cap of Intensity Therapeutics (INTS)?
Intensity Therapeutics currently has a market capitalization of 11.6M USD on BioPharmSignal.
What does Intensity Therapeutics do?
Intratumoral Cancer Therapy Intensity Therapeutics develops medicines administered directly into tumors. Its approach is designed to kill injected tumor cells, expose tumor antigens and stimulate a broader immune response. INT230-6 INT230-6 combines cytotoxic agents with a proprietary dispersion molecule intended to improve penetration throughout solid...
On which exchange is INTS stock listed?
Intensity Therapeutics (INTS) is associated with NASDAQ, United States, Biopharma.
What is INVINCIBLE-4?
Resumption of enrollment in INVINCIBLE-4 in the second quarter of 2026.
Which conditions is Intensity Therapeutics targeting with INVINCIBLE-4?
Intensity Therapeutics is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does Intensity Therapeutics describe recent progress with INVINCIBLE-4?
Resumption of enrollment in INVINCIBLE-4 in the second quarter of 2026.
What is INVINCIBLE-3?
Breast-Cancer Programs The INVINCIBLE-4 study evaluates presurgical INT230-6 in triple-negative breast cancer, while INVINCIBLE-3 studies the candidate in a broader breast-cancer setting.